A method for determining the modification site and cross-linking mode of cross-linked hyaluronic acid
Through liquid chromatography tandem mass spectrometry analysis and fragmentation mode detection, the modification sites and cross-linking methods of hyaluronic acid reacting with BDDE were determined, which solved the identification problems in the prior art, and improved the mechanical properties of cross-linked hyaluronic acid and Application scope.
Patent Information
- Application Number
- CN202211078138.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-09-05
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2042-09-05
AI Technical Summary
The prior art cannot accurately determine the modification sites and crosslinking methods of hyaluronic acid reacting with the crosslinking agent BDDE, which affects the mechanical properties and application scope of crosslinking hyaluronic acid.
By mixing the modified hyaluronic acid oligosaccharides with reducing agents and performing liquid chromatography tandem mass spectrometry analysis, secondary or tertiary tandem mass spectrometry detection is performed using fragmentation modes such as collision-induced dissociation and high-energy fragmentation dissociation to determine the cross-section Modification sites and cross-linking methods of hyaluronic acid.
Accurate identification of crosslinked hyaluronic acid modification sites and crosslinking methods has been achieved, and the mechanical properties and application scope of crosslinked hyaluronic acid products have been improved.
Smart Images

Figure GDA0005012147750000121 
Figure GDA0005012147750000131 
Figure GDA0005012147750000132
Abstract
Description
Technical Field
[0001] The present application belongs to the field of detection technology, and specifically, relates to a method for determining the modification site and cross-linking mode of cross-linked hyaluronic acid. Background Art
[0002] Hyaluronic acid (HA) is a linear non-sulfated glycosaminoglycan composed of repeating disaccharide units: d-glucuronic acid (1→3)-dN-acetylglucosamine (1→4) (e.g. Figure 1 As shown). Hyaluronic acid exists in all vertebrates, and its primary structure is conservative, with the only changes being the molecular weight and polydispersity index of the polymer. Human skin, eyes, and extracellular matrix are rich in hyaluronic acid. Due to its large amount of negative charge, hyaluronic acid has strong hydrophilicity and can therefore be used as a space filler, lubricant, and osmotic buffer. However, soluble hyaluronic acid has poor mechanical properties and is rapidly degraded and cleared in the body, limiting its application as a biomaterial. In order to improve the mechanical properties of hyaluronic acid and increase its resistance to hyaluronidase degradation, it is usually chemically modified or cross-linked to form a hydrogel.
[0003] The most common method for preparing cross-linked hyaluronic acid is to react hyaluronic acid with the cross-linker 1,4-butanediol diglycidyl ether (BDDE) under alkaline conditions to produce a stable covalent ether bond between hyaluronic acid and the cross-linker. During the cross-linking process, the epoxy groups of BDDE react with the nucleophilic groups on the hyaluronic acid molecules to form 1,4-butanediol di(propane-2,3-diol) ether (BDPE) derivatives. Some BDDE cross-linker molecules exist in the form of free hydroxyl groups at both ends, some BDDE molecules are only bound to hyaluronic acid at one end, and some BDDE molecules are bound to hyaluronic acid at both ends (such as Figure 2 , as shown in ac).
[0004] Each nucleophilic group of hyaluronic acid can react with BDDE. There are 7 sites on the disaccharide unit of hyaluronic acid, including the hydroxyl groups connected to the C atoms at positions 2 and 3 of uronic acid (HexA) and the C atoms at positions 1, 4, and 6 of N-acetylglucosamine (GlcNAc), the carboxyl group of HexA, and the amide group of GlcNAc (such as Figure 3 At present, the modification sites that react with BDDE are not clear, so it is also impossible to accurately determine the cross-linking method between HA and BDDE.
[0005] Different modification sites and cross-linking methods may affect the mechanical properties of cross-linked hyaluronic acid, and thus affect the quality and application range of cross-linked products. Determining the modification sites and cross-linking methods of cross-linked hyaluronic acid has important guiding significance for the production and application of cross-linked hyaluronic acid products. Summary of the invention
[0006] In view of the problems existing in the prior art, the present application provides a method for determining the modification site and cross-linking mode of cross-linked hyaluronic acid.
[0007] Specifically, this application involves the following aspects:
[0008] A method for determining the modification site and cross-linking mode of cross-linked hyaluronic acid, characterized in that it comprises the following steps:
[0009] mixing the modified hyaluronic acid oligosaccharide with a reducing agent to obtain a reduced product;
[0010] The reduced product is subjected to liquid chromatography tandem mass spectrometry analysis to obtain separated modified oligosaccharides;
[0011] Performing secondary or tertiary tandem mass spectrometry detection on the separated modified oligosaccharide to obtain a detection result;
[0012] The detection results determine the modification site and cross-linking method of the cross-linked hyaluronic acid.
[0013] Furthermore, the modified hyaluronic acid oligosaccharide is obtained by enzymatically cross-linking hyaluronic acid, and the cross-linked hyaluronic acid is hyaluronic acid cross-linked by 1,4-butanediol diglycidyl ether.
[0014] Furthermore, the fragmentation mode of the secondary or tertiary tandem mass spectrometry detection includes one or both of collision induced dissociation (CID) and high energy fragmentation dissociation (HCD).
[0015] Furthermore, the collision energy of collision induced dissociation (CID) is 15-40, and the collision energy of high energy fragmentation dissociation (HCD) is 40-80.
[0016] Furthermore, the chromatographic conditions for the liquid chromatography tandem mass spectrometry detection are: using a porous graphitized carbon chromatographic column, gradient elution with mobile phase A and mobile phase B, mobile phase A is ammonium formate or ammonium acetate aqueous solution, and mobile phase B is ammonium formate or ammonium acetate in acetonitrile aqueous solution.
[0017] Furthermore, the mass spectrometry conditions are: negative ion scanning mode, sheath gas flow rate of 10-20arb, auxiliary gas flow rate of 0-5arb, spray voltage of 3-4KV, capillary temperature of 250-350°C, and ion lens voltage of 30-70%V.
[0018] Furthermore, the concentration of ammonium formate or ammonium acetate in the ammonium formate or ammonium acetate aqueous solution in the mobile phase A is 5-10 mM.
[0019] Furthermore, the concentration of ammonium formate or ammonium acetate in the acetonitrile aqueous solution of ammonium formate or ammonium acetate in the mobile phase B is 5-10 mM, and the concentration of acetonitrile is 90-95 wt %.
[0020] Furthermore, the column temperature of the liquid chromatography column is 25-35°C.
[0021] Furthermore, the flow rate of the mobile phase in the liquid chromatography-tandem mass spectrometry detection is 0.2-0.4 mL.min -1 .
[0022] The method of the present application can fully separate various modified hyaluronic acid oligosaccharides, and further perform mass spectrometry detection and analysis on the separated modified hyaluronic acid oligosaccharides, so as to determine the modification site and cross-linking method of the cross-linked hyaluronic acid. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 Showing the molecular structure of hyaluronic acid.
[0024] Figure 2 Shows the existing form of BDDE in cross-linked hyaluronic acid.
[0025] Figure 3 Possible cross-linking sites of unsaturated hyaluronan disaccharides are shown.
[0026] Figure 4 Schematic structures of the four most common types of pendant (2-B, 4-B) and cross-linked modified (2-B-2, 4-B-2) fragments in the cross-linked hyaluronic acid degradation products.
[0027] Figure 5 The RS absolute configuration of the BDDE molecule is shown.
[0028] Figure 6 NaBH4 reduction of hyaluronan disaccharide α and β anomers is shown.
[0029] Figure 7 The chromatographic separation of the modified hyaluronic acid oligosaccharides obtained using the separation method of Example 1 is shown.
[0030] Figure 8 The chromatographic separation of the modified hyaluronic acid oligosaccharides obtained using the separation method of Example 2 is shown.
[0031] Fig. 9 The chromatographic separation of the modified hyaluronic acid oligosaccharides obtained using the separation method of Comparative Example 1 is shown.
[0032] Fig.10 The chromatographic separation of the modified hyaluronic acid oligosaccharides obtained using the separation method of Comparative Example 2 is shown.
[0033] Fig.11 Displays the fragment ion diagram of each chromatographic peak in the 2-B structure.
[0034] Fig.12 Displays the fragment ion diagram of each chromatographic peak in the 4-B structure.
[0035] Fig.13 Extracted ion chromatogram showing specific fragment ions generated from each chromatographic peak in the 2-B-2 structure.
[0036] Fig.14 Extracted ion chromatogram showing specific fragment ions generated from each chromatographic peak in the 4-B-2 structure. DETAILED DESCRIPTION
[0037] The present application is further described below in conjunction with examples. It should be understood that the examples are only used to further describe and illustrate the present application and are not used to limit the present application.
[0038] Unless otherwise defined, the technical and scientific terms in this specification have the same meaning as those generally understood by those skilled in the art. Although similar or identical methods and materials as described herein may be used in experiments or practical applications, materials and methods are described herein below. In the event of a conflict, the present specification including the definitions therein shall prevail. In addition, materials, methods and examples are provided for illustration only and are not restrictive. The present application is further described below in conjunction with specific embodiments, but is not intended to limit the scope of the present application.
[0039] Theoretically, there are 7 sites in each HA disaccharide unit that can react with BDDE, including the hydroxyl groups connected to the C atoms at positions 2 and 3 of uronic acid (HexA) and C atoms at positions 1, 4, and 6 of N-acetylglucosamine (GlcNAc), the carboxyl group of HexA, and the amide group of GlcNAc (e.g. Figure 3 ). Deprotonated hydroxyl groups are more nucleophilic than carboxyl and amide groups. In addition, any ester formed with HA carboxyl groups is likely to undergo hydrolysis under alkaline conditions. Therefore, hydroxyl groups are the most likely sites to react with BDDE and form stable ether bonds with the crosslinker. The relative trends of the binding abilities of different hydroxyl groups to BDDE are not clear, but may be related to factors such as the steric differences between primary and secondary alcohols, conformational effects of polymers, differences in hydroxyl acidity, and differences in reaction conditions.
[0040] Since BDDE-crosslinked HA has a large molecular weight and poor solubility in water, when characterizing its degree of crosslinking, a tool enzyme (such as hyaluronidase or chondroitinase ABC, etc.) is usually used to degrade it into oligosaccharide fragments of different sizes. During the enzymatic hydrolysis process, a carbon-carbon double bond (such as 4-5 carbon atoms of hexuronic acid) is formed between the oligosaccharide products. Figure 3Oligosaccharide fragments can be divided into two types: hanging modified fragments and cross-linked modified fragments. The schematic structures of the four types of hanging (2-B, 4-B) and cross-linked (2-B-2, 4-B-2) fragments with the highest proportion in degradation products are shown in Figure 4 .
[0041] It should be pointed out that, as mentioned above, there are many ways to connect BDDE to the HA sugar unit. Figure 4 Only one cross-linking situation (2-B(GlcNAc-OH6)) in a certain type of structure (such as 2-B) is shown. In addition, due to the different absolute configurations (R or S) of the 2' and 2" C atoms of the BDDE cross-linker (such as Figure 5 As shown in Figure 5, a specific oligosaccharide (such as 2-B(GlcNAc-OH6)) may also be affected by the absolute configuration of BDDE to form different isomers.
[0042] On the other hand, the sugar unit at the end of the oligosaccharide chain undergoes C1 isomerization during the formation of hemiacetal, resulting in the formation of two non-corresponding isomers (α and β), which are anomers of each other. Taking the unsaturated hyaluronic acid disaccharide as an example, the hydroxyl group connected to the C atom at position 1 of GlcNAc may be located on the same side or opposite side of the sugar ring plane as the C atom at position 6, forming β and α anomers respectively (such as Figure 6 ). The presence of anomers further increases the difficulty of separation and structural analysis of modified hyaluronic acid oligosaccharides.
[0043] In view of the problems existing in the prior art, the present application provides a method for determining the modification site and cross-linking mode of cross-linked hyaluronic acid, comprising the following steps:
[0044] mixing the modified hyaluronic acid oligosaccharide with a reducing agent to obtain a reduced product;
[0045] The reduced product is subjected to liquid chromatography tandem mass spectrometry (LC-MS, or liquid chromatography-mass spectrometry) detection to obtain separated modified oligosaccharides;
[0046] The separated modified oligosaccharide is subjected to secondary or tertiary liquid chromatography tandem mass spectrometry detection to obtain a detection result;
[0047] The modification site and cross-linking method of the cross-linked hyaluronic acid are determined based on the detection results.
[0048] In the present application, modified hyaluronic acid oligosaccharides refer to chemically modified hyaluronic acid oligosaccharides, for example, various hyaluronic acid oligosaccharides obtained by enzymatic hydrolysis of cross-linked hyaluronic acid using hyaluronidase or chondroitinase.
[0049] In a specific embodiment, the cross-linked hyaluronic acid is cross-linked hyaluronic acid by 1,4-butanediol diglycidyl ether. Among them, the main modified hyaluronic acid oligosaccharides obtained after the degradation of the cross-linked hyaluronic acid are as follows Figure 4 As shown, there are four types of structures, including 2-B, 4-B, 2-B-2, and 4-B-2.
[0050] In the present application, the modified hyaluronic acid oligosaccharide is mixed with a reducing agent to obtain a reduced product, and the reducing agent can be a reducing agent commonly used in the art, and those skilled in the art can make a conventional selection, for example, it can be sodium borohydride (NaBH4). In the specific operation, an excess of sodium borohydride can be used to react with the modified hyaluronic acid oligosaccharide, and then the remaining sodium borohydride that does not participate in the reaction is neutralized.
[0051] As mentioned above, the sugar unit at the end of the oligosaccharide chain undergoes C1 isomerization during the formation of hemiacetal, resulting in the formation of two isomers α and β. In order to eliminate the influence of the two isomers on chromatographic separation, a reducing agent can be used to reduce the sugar unit at the end of the oligosaccharide and form an open ring structure (such as Figure 6 It should be noted that if the hydroxyl group on the anomeric C is modified by BDDE, the reduction reaction cannot occur.
[0052] LC-MS uses liquid chromatography as the separation system and mass spectrometry as the detection system. The components in the sample are separated from each other in the liquid chromatography part. After being ionized, the mass analyzer of the mass spectrometer separates the ion fragments according to the mass-to-nuclear ratio, and the mass spectrum is obtained by the detector. LC-MS embodies the complementary advantages of chromatography and mass spectrometry, combining the high separation ability of chromatography for complex samples with the advantages of MS with high selectivity, high sensitivity and ability to provide relative molecular mass and structural information. It has been widely used in many fields such as drug analysis, food analysis and environmental analysis.
[0053] Wherein, a porous graphitized carbon chromatographic column is used in the liquid chromatography-mass spectrometry technology, and gradient elution is performed with mobile phase A and mobile phase B. In a specific embodiment, the porous graphitized carbon chromatographic column is a Hypercarb porous graphitized carbon chromatographic column.
[0054] Mobile phase A is an aqueous solution of ammonium formate or ammonium acetate, and mobile phase B is an aqueous solution of ammonium formate or ammonium acetate in acetonitrile.
[0055] In a specific embodiment, the mobile phase A is an aqueous solution of ammonium formate, wherein the concentration of ammonium formate is 5-10 mM, for example, 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, 10 mM.
[0056] In a specific embodiment, the pH of mobile phase A can be adjusted to 2.5-3.5, for example, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5. Conventional acids, bases or buffers can be used to adjust the pH of mobile phase A, for example, formic acid can be used.
[0057] In a specific embodiment, mobile phase A is an aqueous solution of ammonium acetate, wherein the concentration of ammonium acetate is 5-10 mM, for example, 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, 10 mM.
[0058] In a specific embodiment, the pH of mobile phase A can be adjusted to 2.5-3.5, for example, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5. Conventional acids, bases or buffers can be used to adjust the pH of mobile phase A, for example, acetic acid can be used.
[0059] In a specific embodiment, mobile phase B is an acetonitrile aqueous solution of ammonium formate, wherein the concentration of ammonium formate is 5-10mM, for example, 5mM, 6mM, 7mM, 8mM, 9mM, 10mM. The concentration of acetonitrile is 90-95wt%, for example, 90wt%, 91wt%, 92wt%, 93wt%, 94wt%, 95wt%.
[0060] In a specific embodiment, the pH of mobile phase B can be adjusted to 2.5-3.5, for example, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5. The pH of mobile phase A can be adjusted using conventional acids, bases or buffers, for example, formic acid can be used.
[0061] In a specific embodiment, mobile phase B is an acetonitrile aqueous solution of ammonium acetate, wherein the concentration of ammonium acetate is 5-10 mM, for example, 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, 10 mM. The concentration of acetonitrile is 90-95 wt%, for example, 90 wt%, 91 wt%, 92 wt%, 93 wt%, 94 wt%, 95 wt%.
[0062] In a specific embodiment, the pH of mobile phase B can be adjusted to 2.5-3.5, for example, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5. The pH of mobile phase A can be adjusted using conventional acids, bases or buffers, for example, acetic acid can be used.
[0063] In a specific embodiment, mobile phase A is 5 mM ammonium formate aqueous solution, and the pH is adjusted to 3 with formic acid. Mobile phase B is 5 mM ammonium formate in acetonitrile aqueous solution, and the pH is adjusted to 3 with formic acid. The acetonitrile concentration is 90 wt%.
[0064] In a specific embodiment, mobile phase A is a 5 mM ammonium acetate aqueous solution adjusted to pH 3 with acetic acid, and mobile phase B is a 5 mM ammonium acetate acetonitrile aqueous solution adjusted to pH 3 with acetic acid, and the acetonitrile concentration is 90 wt%.
[0065] In a specific embodiment, the gradient elution process of the present application can be divided into five stages, specifically:
[0066] In the first stage, the volume ratio of mobile phase A to mobile phase B was (90-100):(10-0);
[0067] In the second stage, the volume ratio of mobile phase A to mobile phase B was (75-85):(25-15);
[0068] In the third stage, the volume ratio of mobile phase A to mobile phase B was (40-50):(60-50);
[0069] In the fourth stage, the volume ratio of mobile phase A to mobile phase B is (0-10):(100-90);
[0070] In the fifth stage, the volume ratio of mobile phase A to mobile phase B is (90-100):(10-0).
[0071] In a specific embodiment, the gradient elution process of the present application can be divided into five stages, specifically:
[0072] In the first stage, the volume ratio of mobile phase A to mobile phase B was 95:5;
[0073] In the second stage, the volume ratio of mobile phase A to mobile phase B was 78:22;
[0074] In the third stage, the volume ratio of mobile phase A to mobile phase B was 45:55;
[0075] In the fourth stage, the volume ratio of mobile phase A to mobile phase B was 0:100;
[0076] In the fifth stage, the volume ratio of mobile phase A to mobile phase B was 95:5.
[0077] In a specific embodiment, the gradient elution process of the present application is:
[0078] In the first stage, 0–3 min, the volume ratio of mobile phase A to mobile phase B was 95:5;
[0079] In the second stage, from 3 to 100 min, the volume ratio of mobile phase A to mobile phase B was 78:22;
[0080] The third stage, 100-105 min, the volume ratio of mobile phase A to mobile phase B was 45:55;
[0081] The fourth stage, 105-115 min, the volume ratio of mobile phase A to mobile phase B was 0:100;
[0082] In the fifth stage, 115-140 min, the volume ratio of mobile phase A to mobile phase B was 95:5.
[0083] In a specific embodiment, the column temperature of the chromatographic column in the liquid chromatography-mass spectrometry technology is 25-35°C, for example, it can be 25°C, 26°C, 27°C, 28°C, 29°C, 30°C, 31°C, 32°C, 33°C, 34°C, or 35°C.
[0084] In a specific embodiment, the flow rate of the mobile phase used in the liquid chromatography-mass spectrometry technique is 0.2-0.4 mL.min -1 , for example, it can be 0.2mL.min -1 、0.3mL.min -1 、0.4mL.min -1 .
[0085] In a specific embodiment, the mass spectrometry conditions of the liquid chromatography-mass spectrometry technique are:
[0086] In negative ion scanning mode, the sheath gas flow rate was 10-20 arb, the auxiliary gas flow rate was 0-5 arb, the spray voltage was 3-4 KV, the capillary temperature was 250-350°C, and the ion lens voltage was 50%V.
[0087] In a specific embodiment, the mass spectrometry conditions of the liquid chromatography-mass spectrometry technique are:
[0088] In negative ion scanning mode, the sheath gas flow rate was 15 arb, the auxiliary gas flow rate was 3 arb, the spray voltage was 3.5 KV, the capillary temperature was 275.00 °C, and the ion lens voltage was 50% V.
[0089] Mass spectrometry detection of the separated modified oligosaccharides can be performed by online secondary tandem mass spectrometry (LC-MS / MS) or online tertiary tandem mass spectrometry (LC-MS / MS / MS) to fragment the separated modified oligosaccharides, and identify the modification site and cross-linking mode of the cross-linker through the fragment ions.
[0090] There are many types of fragmentation modes commonly used in structural analysis, for example, there are electron capture fragmentation (ECD), electron transfer fragmentation (ETD), collision induced dissociation (CID), electron dissociation (EDD) collision activated dissociation (CAD), etc. Different fragmentation modes have different fragmentation efficiencies. The modified hyaluronic acid oligosaccharides separated in this application contain a variety of new oligosaccharide structures, and there are no corresponding fragmentation modes and application modules in the prior art. Therefore, in order to obtain modified hyaluronic acid oligosaccharide fragment ions with richer structural information, the inventors have determined the types of fragmentation modes through a large number of experimental studies and creative work.
[0091] In the present application, the fragmentation mode of the secondary or tertiary tandem mass spectrometry detection includes one or both of collision induced dissociation (CID) and high energy fragmentation dissociation (HCD).
[0092] In a specific embodiment, collision induced dissociation (CID) fragmentation mode is used.
[0093] In a specific embodiment, a high energy fragmentation dissociation (HCD) fragmentation mode is used.
[0094] In a specific embodiment, two fragmentation modes, collision induced dissociation (CID) and high energy fragmentation dissociation (HCD), are used.
[0095] In a specific embodiment, the collision energy of collision induced dissociation (CID) is 15-40.
[0096] In a specific embodiment, the collision energy of the high energy fragmentation dissociation (HCD) is 40-80.
[0097] In a specific embodiment, the parameters of the tandem mass spectrometer in CID mode are set as follows: Iso width (m / z) is 3.0, normalized collision energy is 25, Act Q, 0.25, and action time is 10 ms.
[0098] In a specific embodiment, the parameters of the tandem mass spectrometer in HCD mode are set as follows: Iso width (m / z) is 3.0, normalized collision energy is 60, Act Q, 0.25, and action time is 0.1 ms.
[0099] Currently, there is no method to determine the modification site and cross-linking mode of cross-linked hyaluronic acid. The method of the present application can fully separate various hyaluronic acid oligosaccharides modified with BDDE, and further determine the sugar unit or specific hydroxyl site where the hyaluronic acid disaccharide unit undergoes cross-linking reaction with BDDE through secondary or tertiary liquid chromatography tandem mass spectrometry analysis, thereby determining the cross-linking mode of hyaluronic acid and BDDE.
[0100] Example
[0101] Example 1
[0102] (1) Enzymatic hydrolysis of cross-linked hyaluronic acid
[0103] Enzyme hydrolysis buffer: take about 2.74g of sodium dihydrogen phosphate dihydrate and about 0.35g of disodium hydrogen phosphate anhydrous, accurately weigh, place in the same 100ml volumetric flask, add water to dissolve and quantitatively dilute to the scale, shake well, accurately measure 10ml and place in a 100ml volumetric flask, quantitatively dilute to the scale with water, shake well, adjust the pH to 6.6 with 1mol / L sodium hydroxide solution, sterilize at 121℃ for 10 minutes, and cool.
[0104] Hyaluronidase solution (10,000 units / ml): Take 1 tube of hyaluronidase (50,000 units) (Huaxi Biotechnology Co., Ltd.), transfer it to a 5 ml volumetric flask, quantitatively dilute it to the scale with enzymatic buffer, shake well, and obtain.
[0105] The enzymatic hydrolyzate is the test solution: take an appropriate amount of cross-linked hyaluronic acid powder or hydrogel (Huaxi Biotechnology Co., Ltd.) (equivalent to about 10 mg of cross-linked hyaluronic acid), accurately weigh, place in a 20 ml headspace bottle, add 1 ml of enzymatic hydrolysis buffer, 0.5 ml of water, seal, press cap, sterilize in an oven at 121°C for 10 minutes, cool, use a syringe to take 1 ml of hyaluronidase solution (10,000 units / ml), inject it into the headspace bottle, place in a water bath constant temperature oscillator, set the temperature to 42°C, the speed to 190 rpm, enzymatic hydrolysis for 24 hours, transfer to a 5 ml volumetric flask, wash the headspace bottle once with 0.5 ml of 0.1 mol / L hydrochloric acid solution, wash the headspace bottle once with an appropriate amount of water, add the washing solution into the same volumetric flask, dilute to the scale with water, shake well, filter, and obtain.
[0106] (2) Sample purification
[0107] The above obtained enzymatic hydrolysate was transferred to an ultrafiltration tube (500 μl, molecular weight cut-off of 10 kDa), and centrifuged at 5000 rcf for 20 min. 400 μl H2O was added to the upper tube, and centrifuged at 5000 rcf for 20 min, retaining the filtrate in the bottom tube. The above two centrifugations increased the recovery rate of the modified hyaluronic acid oligosaccharide, and the concentration of the modified hyaluronic acid oligosaccharide sample finally obtained was about 1 mg / ml.
[0108] (3) Sample reduction
[0109] Take 4 ml of the filtrate obtained in step (2) into a sample bottle, slowly add 0.3 ml of 0.5 M NaBH4 solution (the NaBH4 solution is freshly prepared and used), and react at 42°C for 1 hour (shake once every 20 minutes). After the reaction is completed, add 0.35 ml of 0.5 M acetic acid to the sample bottle to neutralize the remaining NaBH4 that has not participated in the reaction. The above sample is freeze-dried and redissolved in 200 μl H2O. The final concentration of the modified hyaluronic acid oligosaccharide is about 20 mg / ml.
[0110] (4) LC-MS separation
[0111] The modified hyaluronic acid oligosaccharides obtained in step (3) are separated using LC-MS. The specific chromatographic conditions used in LC-MS are as follows:
[0112] Chromatographic column: Hypercarb porous graphitized carbon chromatographic column (column length 150 cm, column inner diameter 4.6 mm, filler particle size 5 μm).
[0113] Chromatographic conditions: Mobile phase A: 5 mM ammonium formate aqueous solution, adjusted to pH 3.0 with formic acid; Mobile phase B: 5 mM ammonium formate 90% acetonitrile aqueous solution, adjusted to pH 3.0 with formic acid; Column temperature: 26 °C; Flow rate: 0.2 mL.min -1 ; The elution gradient is shown in Table 1. The injection volume is 3 μl.
[0114] Table 1
[0115] Serial number Time (min) A(%) B(%) curve 1 0 95 5 5 2 3 78 22 5 3 100 45 55 5 4 105 0 100 5 5 115 0 100 5 6 115.01 95 5 5 7 140 95 5 5
[0116] The eluents from 0-18min and 115-140min were introduced into waste liquid, and the rest were introduced into mass spectrometry.
[0117] The mass spectrometry conditions (LTQ-Orbitrap, Thermo Fisher Scientific) were: negative ion scan mode; sheath gas flow rate 15 arb; auxiliary gas flow rate 3 arb; spray voltage 3.5 KV; capillary temperature 275.00°C; ion lens voltage 50%V.
[0118] The separation of modified hyaluronic acid oligosaccharides obtained by LC-MS is shown in Figure 7 shown.
[0119] Depend on Figure 7It can be seen that 2-B presents 5 chromatographic peaks in the chromatogram; 4-B presents 3 chromatographic peaks in the chromatogram. After reduction, 2-B-2 can be further divided into two types of structures. The m / z of the first type of structure is 963.36 (z = -1), and the two GlcNAc sugar units at the reducing end of the disaccharide in this type of structure are reduced by NaBH4 to form an open ring structure; the m / z of the second type of structure is 961.35 (z = -1), and only one of the two GlcNAc sugar units at the reducing end of the disaccharide in this type of structure is reduced by NaBH4 to form an open ring structure, indicating that the hydroxyl group connected to the C-1 position of the other unreduced GlcNAc sugar unit is modified by the BDDE molecule. Similar to 2-B-2, 4-B-2 can be further divided into two types of structures after reduction. The m / z of the first type of structure is 670.74 (z = -2). In this type of structure, the two GlcNAc sugar units at the reducing end of the tetrasaccharide and disaccharide are reduced by NaBH4 to form an open ring structure; the m / z of the second type of structure is 669.73 (z = -2). In this type of structure, only one of the two GlcNAc sugar units at the reducing end of the oligosaccharide is reduced by NaBH4 to form an open ring structure, indicating that the hydroxyl group (-OH1) connected to the C position 1 of the other unreduced GlcNAc sugar unit is modified by the BDDE molecule. According to the mechanism of action of hyaluronidase, the structure in which the GlcNAc (-OH1) at the reducing end of 2-B-2 and 4-B-2 is modified by BDDE may come from the reducing end of the hyaluronic acid sugar chain.
[0120] Example 2
[0121] The difference between Example 2 and Example 1 is that the sample reduction in step (3) in Example 1 is not included, that is, the modified hyaluronic acid oligosaccharide sample obtained in step (2) is directly subjected to LC-MS separation, and the other steps and detection conditions are the same as those in Example 1.
[0122] The separation of modified hyaluronic acid oligosaccharides obtained by LC-MS is shown in Figure 8 As shown. Figure 8 It can be seen that the components cannot be fully separated. This is because not performing sample reduction will cause two effects: first, due to the presence of isomers, the complexity of the target structure is doubled, and the peaks of each isomer affect each other, resulting in insufficient chromatographic separation; second, the two different types of structures in 2-B-2 and 4-B-2 ( Figure 7 ) have exactly the same mass-to-nuclear ratio before reduction and cannot be distinguished by extracted particle flow diagram (EIC), which increases the complexity of the spectrum.
[0123] Example 3
[0124] The hyaluronic acid oligosaccharides separated in Example 1 were subjected to mass spectrometry detection, using collision induced dissociation (CID) and high energy fragmentation dissociation (HCD) fragmentation modes. The parameters of the tandem mass spectrometry in CID mode were set as follows: Iso width (m / z) was 3.0, the normalized collision energy was 25, Act Q, 0.25, and the action time was 10ms. The parameters of the tandem mass spectrometry in HCD mode were set as follows: Iso width (m / z) was 3.0, the normalized collision energy was 60, Act Q, 0.25, and the action time was 0.1ms. According to the fragmentation of hyaluronic acid oligosaccharides, the structure and modification site of each modified hyaluronic acid oligosaccharide were determined by diagnostic ions. Fig.11 It is the fragment ion diagram of each chromatographic peak in the 2-B structure. Fig.12 It is the fragment ion diagram of each chromatographic peak in the 4-B structure. Fig.13 This is the extracted ion chromatogram of the specific fragment ions produced by each chromatographic peak in the 2-B-2 structure. Fig.14 This is the extracted ion chromatogram of the specific fragment ions produced by each chromatographic peak in the 4-B-2 structure.
[0125] The above results are summarized in Tables 2 to 4. Among them, Table 2 is the analysis results of 2-B and 4-B, Table 3 is the analysis results of 2-B-2, and Table 4 is the analysis results of 4-B-2. Representative chromatographic peaks are selected below to illustrate the expression of the modification site / oligosaccharide structure in the table. The structure of 2-B peak 1 is described as △GlcA-GlcNAc (open ring, -OH4), where "△GlcA" means that a double bond of glucuronic acid is formed between the C atoms at positions 4 and 5; "GlcNAc (open ring, -OH4)" means that it is reduced by NaBH4 to form an open ring structure of N-acetylglucosamine, and the hydroxyl group connected to the C atom at position 4 of the sugar unit is bound to the BDDE cross-linker. The structures of 2-B-2 (963.36) peaks 1-5, 7, and 9 are expressed as GlcNAc (open ring)-B-GlcNAc (open ring), indicating that two unsaturated hyaluronic acid disaccharides are connected by a BDDE cross-linker, and the sugar units bound to BDDE are all reduced by NaBH4 to form an open-ring structure of N-acetylglucosamine.
[0126] Table 2
[0127]
[0128]
[0129] Table 3
[0130]
[0131] Table 4
[0132]
[0133] Comparative Example 1
[0134] Comparative Example 1 The difference between Comparative Example 1 and Example 1 is that the specific chromatographic conditions are different, and the other steps and detection conditions are the same as those of Example 1.
[0135] Specifically, the difference between Comparative Example 1 and Example 1 is that the mobile phase A and the mobile phase B used are different. The mobile phase A used in Comparative Example 1 is a 0.1% formic acid aqueous solution, and the mobile phase B is a 0.1% formic acid acetonitrile solution.
[0136] The separation of modified hyaluronic acid oligosaccharides obtained by LC-MS is shown in Fig. 9 As shown. Fig. 9 It can be seen that the elution of each modified hyaluronic acid oligosaccharide component is insufficient or the separation is poor, and effective separation cannot be achieved.
[0137] Comparative Example 2
[0138] The difference between Comparative Example 2 and Example 1 is that the chromatographic column used is different, and the other steps and detection conditions are the same as those of Example 1.
[0139] Specifically, the difference between Comparative Example 2 and Example 1 is that the chromatographic column used is different. The chromatographic column used in Comparative Example 2 is an amino column BEH Amide chromatographic column (2.1 mm×150 mm, 1.9 μm).
[0140] The separation of modified hyaluronic acid oligosaccharides obtained by LC-MS is shown in Fig.10 As shown. Fig.10 It can be seen that the separation degree of each modified hyaluronic acid oligosaccharide component is poor, and effective separation of each component cannot be achieved.
[0141] Comparative Example 3
[0142] The only difference between Comparative Example 3 and Example 3 is that different fragmentation energy is used, and the other steps and detection conditions are the same as those of Example 3.
[0143] The hyaluronic acid oligosaccharides separated in Example 1 were subjected to mass spectrometry detection using CID or HCD fragmentation mode. The normalized collision energy in the CID fragmentation mode was less than 15 or greater than 40, and the normalized collision energy in the HCD fragmentation mode was set to less than 40 or greater than 80. At this collision energy, the parent ion was not fully fragmented or the fragment ion intensity was too low to be distinguished from the instrument noise. The above fragmentation conditions cannot achieve the analysis of the cross-linking mode and modification site of the target.
Claims
1. A method for determining the modification site and cross-linking mode of cross-linked hyaluronic acid, characterized in that: The following steps are involved: mixing the modified hyaluronic acid oligosaccharide with a reducing agent to obtain a reduced product; The reduced product is subjected to liquid chromatography tandem mass spectrometry analysis to obtain separated modified oligosaccharides; Performing secondary or tertiary tandem mass spectrometry detection on the separated modified oligosaccharide to obtain a detection result; Determining the modification site and cross-linking method of the cross-linked hyaluronic acid based on the detection results; Wherein, the modified hyaluronic acid oligosaccharide is obtained by enzymatically cross-linking hyaluronic acid, and the cross-linked hyaluronic acid is hyaluronic acid cross-linked by 1,4-butanediol diglycidyl ether; The fragmentation mode of the secondary or tertiary tandem mass spectrometry detection comprises one or both of collision induced dissociation (CID) and high energy fragmentation dissociation (HCD); The collision energy for collision-induced dissociation (CID) is 15-40, and the collision energy for high-energy fragmentation dissociation (HCD) is 40-80; The chromatographic conditions of the liquid chromatography tandem mass spectrometry detection are: using a porous graphitized carbon chromatographic column, gradient elution with mobile phase A and mobile phase B, mobile phase A is ammonium formate or ammonium acetate aqueous solution, and mobile phase B is ammonium formate or ammonium acetate in acetonitrile aqueous solution; Determining the modification site and cross-linking mode of the cross-linked hyaluronic acid based on the detection results means determining the sugar unit or specific hydroxyl site at which the hyaluronic acid disaccharide unit undergoes a cross-linking reaction with 1,4-butanediol diglycidyl ether based on the detection results, thereby determining the cross-linking mode of hyaluronic acid and 1,4-butanediol diglycidyl ether.
2. The method according to claim 1, characterized in that The mass spectrometry conditions of the liquid chromatography tandem mass spectrometry detection are: negative ion scanning mode, sheath gas flow rate of 10-20arb, auxiliary gas flow rate of 0-5arb, spray voltage of 3-4KV, capillary temperature of 250-350°C, and ion lens voltage of 30-70%V.
3. The method according to claim 1, characterized in that The concentration of ammonium formate or ammonium acetate in the ammonium formate or ammonium acetate aqueous solution in mobile phase A is 5-10 mM.
4. The method according to claim 1, characterized in that: The concentration of ammonium formate or ammonium acetate in the acetonitrile aqueous solution of ammonium formate or ammonium acetate in mobile phase B is 5-10 mM, and the concentration of acetonitrile is 90-95 wt %.
5. The method according to claim 1, characterized in that The column temperature of the liquid chromatography is 25-35°C.
6. The method according to claim 1, characterized in that The flow rate of the mobile phase in liquid chromatography-tandem mass spectrometry detection is 0.2-0.4 mL.min -1 .
